United States Patent 7,736,670: Scope, Claims, and US Patent Landscape for Pulmonary Composite Particle Milling
What does US 7,736,670 claim, in plain technical scope?
US 7,736,670 claims a process for making composite active particles for pulmonary administration, where an additive material becomes fused to the surface of an active material particle during a specific kind of milling that breaks agglomerates and yields even distribution of additive on active. The additive is selected to promote dispersal upon inhaler actuation.
Core technical thesis
The patent ties together five requirements:
- Milling mechanism that breaks agglomerates of both:
- active particles, and
- additive particles
- Even dispersal of additive material over active particles.
- Surface fusion of additive particles to active particle surfaces.
- Additive material is functionally defined by performance:
- it promotes dispersal of composite particles upon actuation of an inhaler.
- The process is implemented via one of three milling modalities:
- constriction milling in fluid under pressure,
- compression in a predetermined gap,
- jet milling with active-additive particles.
Clause-level anchoring to pulmonary performance
Claims introduce inhalation-relevant particle metrics:
- reducing MMAD of active by at least 10%
- reducing MMAD of additive by at least 10%
- limiting composite MMAD to ≤ 10 μm after milling
They also add optional downstream steps:
- aggregation modification (including deagglomeration)
- adding liquid and drying (including spray drying or freeze drying)
Additive identity options (substitutable embodiments)
Additive material is exemplified and limited in dependent claims to:
- amino acids
- phospholipids
- metal stearates
Product and formulation coverage
The patent includes:
- composite active particles as made by claim 1
- coatings described as discontinuous and ≤ 1 μm thick
- dry powder inhaler (DPI) formulations
- pressurized metered dose inhaler (pMDI) formulations with propellant
What is the claim architecture and how broad is the protection?
Claim 1 (independent): method with fused additive and inhaler-dispersal functional limitation
Claim 1 is the central scope engine. It is broad because it does not define:
- the specific active ingredient,
- the specific additive chemistry beyond “suitable for promotion of dispersal,”
- a specific inhaler type in the milling step itself.
It becomes structured by five elements:
(A) Milling in the presence of active + additive
Particles are milled in the presence of additive particles so that:
- agglomerates of active and additive are broken up,
- additive disperses and distributes evenly over active,
- additive becomes fused to the surface of active particles.
(B) Additive function
Additive is “suitable for the promotion of dispersal of the composite active particles upon actuation of an inhaler.”
This is a functional performance limitation that can reduce invalidity risk from overbreadth, while still leaving considerable selection latitude.
(C) Milling modality alternatives (three routes)
Claim 1 then defines the milling step as one of:
-
Constricted passage under pressure (fluid milling)
- passing mixture through a constriction under pressure
-
Compression in a predetermined gap
- compressing mixture in a gap of predetermined width
-
Jet milling
- jet milling additive particles with active particles to provide breakup and fusion/dispersal
Claim 1 therefore covers multiple equipment categories under one overarching concept.
(D) Same functional outcome tied to milling
All three milling routes are linked to the same required outcomes:
- breakup of agglomerates of both active and additive,
- dispersal/distribution of additive over active,
- additive fused to active surfaces.
(E) Inhaler performance tie-in
The dispersal-promoting property is not quantified in claim 1. It is embedded as a suitability requirement.
How do dependent claims narrow MMAD, geometry, and post-processing?
Particle-size narrowing
- Claim 2: MMAD of active reduced by ≥ 10% during milling
- Claim 3: MMAD of additive reduced by ≥ 10% during milling
- Claim 4: composite particle MMAD ≤ 10 μm after milling
These limitations are the most direct quantitative constraints in the family you supplied.
Aggregation control
- Claim 5: processing step changes degree of aggregation
- Claim 6: processing step is a deagglomeration step
This extends scope to post-milling handling that targets agglomeration states, which is common in DPI feedstock preparation.
Wetting/drying operations
- Claim 7: add liquid after milling, then drying to remove liquid
- Claim 8: drying is spray drying
- Claim 9: liquid evaporated
- Claim 10: drying is freeze drying
These claims broaden implementation options and can matter for infringement because drying method is often varied across products.
Additive identity narrowing
- Claim 11: additive comprises an amino acid
- Claim 12: additive comprises a phospholipid
- Claim 13: additive comprises a metal stearate
This is a practical narrowing that can be important for validity and for mapping to known lipid/surfactant and glidant-like excipient strategies.
Specific milling hardware/parameters
- Claim 14: gap not more than 10 mm for the compressive milling embodiment
- Claim 15: milling performed using a hybridiser method
This suggests claim coverage for specific processing vendors’ equipment paradigms, not just generic milling.
What is claimed on the product side (composite particles and formulations)?
Composite particles “as made”
- Claim 16: composite active particles for use in a pharmaceutical composition as made by claim 1
- Claim 17: additive forms a coating on active particle surfaces
- Claim 18: coating is discontinuous
- Claim 19: coating thickness ≤ 1 μm
These claims are important because they change the infringement analysis from “how you made it” (process) into “what the product looks like” (structure) even though Claim 16 is still tied to “as made.”
Formulations
- Claim 20: pharmaceutical composition is a dry powder, suitable for DPI
- Claim 21: composition is the one made by the claim 1 method
- Claim 22: further comprises propellant and is suitable for pMDI
This gives coverage across common inhalation product formats: DPI and pMDI.
What does the claim set imply about infringement design-arounds?
Given your claim text, the primary infringement “hooks” are:
- Fusion of additive onto active particle surfaces (not merely mixing)
- Even distribution over active surfaces
- Milling approach within the three modality windows
- Additive functionality (dispersal on inhaler actuation)
- Size/MMAD constraints when dependent claims are asserted
- Product structure: discontinuous coating ≤ 1 μm when dependent claims are asserted
- Formulation format (DPI vs pMDI) in dependent claims
Practical design-around levers (conceptual)
- Avoid “fused to surface” outcome by using additives that remain physically blended rather than surface-attached.
- Use a preparation method outside constriction/compression/jet milling embodiments, while keeping the rest of the particle architecture non-infringing.
- Ensure particle size outcomes do not meet dependent MMAD constraints if you want to avoid dependent claim coverage.
- Avoid the exact coating structure in dependent claims (discontinuous coating ≤ 1 μm), if this is required for infringement theory.
US patent landscape for composite particle milling and inhaler dispersal: what the landscape will track
You provided only the claim text and not the patent’s full publication data. Without bibliographic anchors (publication number, priority date, assignee, inventor set, related family), a complete, accurate US landscape map cannot be constructed without risking incorrect attribution to the wrong document family.
However, the landscape for this invention will typically cluster around these themes in US filings:
- Composite particle engineering for pulmonary delivery
- Surface-coating or adhesion of excipients onto drug particles
- Particle size reduction methods with additive presence
- Dry powder inhaler and pMDI formulations using tailored particle morphology
- Jet milling and high-shear milling with additive co-processing
- MMAD targeting and dispersibility metrics
- Use of amino acids, phospholipids, and metal stearates as dispersibility enhancers/glidants/surface modulators
In enforcement and freedom-to-operate (FTO) terms, the prior art that is most relevant is typically US patent literature that discloses:
- co-milling active + additive to achieve surface attachment,
- inhalation-use composite particles with dispersibility improvement,
- specific milling equipment (jet mills, constriction-based micronizers, and gap-compression/hybridiser systems),
- and excipient chemistry overlapping amino acids/phospholipids/metal stearates.
Claim-by-claim scope map (what must be present for coverage)
| Claim |
Coverage type |
Required technical elements (condensed) |
| 1 |
Independent method |
Milling with additive present to break active+additive agglomerates; even distribution of additive on active; additive fused to active surface; additive suitable to promote dispersal on actuation; milling by constriction fluid under pressure OR compressive gap OR jet milling |
| 2 |
Dependent |
Active MMAD reduced ≥ 10% during milling |
| 3 |
Dependent |
Additive MMAD reduced ≥ 10% during milling |
| 4 |
Dependent |
Composite particle MMAD ≤ 10 μm after milling |
| 5 |
Dependent |
Post-milling processing changes aggregation degree |
| 6 |
Dependent |
Post-milling step is deagglomeration |
| 7 |
Dependent |
Add liquid after milling; dry to remove liquid |
| 8 |
Dependent |
Drying is spray drying |
| 9 |
Dependent |
Drying includes evaporation of liquid |
| 10 |
Dependent |
Drying is freeze drying |
| 11-13 |
Dependent |
Additive is amino acid / phospholipid / metal stearate |
| 14 |
Dependent |
Compressive milling gap ≤ 10 mm |
| 15 |
Dependent |
Milling performed using hybridiser method |
| 16 |
Product (as made) |
Composite active particles for pulmonary use as made by claim 1 |
| 17-19 |
Dependent product structure |
Additive forms discontinuous coating on active surface; coating thickness ≤ 1 μm |
| 20-22 |
Formulation |
DPI dry powder suitable for DPI (and/or made by claim 1); pMDI with propellant |
Key Takeaways
- US 7,736,670 is centered on a co-processing milling method that yields composite particles where an additive is fused to the active particle surface to improve inhaler dispersal.
- Claim 1 covers three milling mechanics: constriction under pressure, compression in a predetermined gap, and jet milling, all tied to the same fusion and dispersal outcome.
- The most litigation-relevant narrowing levers are MMAD reduction/limits (claims 2-4), aggregation modification (claims 5-6), and coating structure and thickness (claims 17-19).
- The patent also extends into product and formulation territory for DPI and pMDI, with excipient identity narrowing for amino acids, phospholipids, and metal stearates (claims 11-13).
FAQs
1) Is the dispersibility of the composite particles quantified in claim 1?
No. Claim 1 uses a functional suitability statement that the additive is suitable to promote dispersal upon inhaler actuation, without numerical performance thresholds.
2) Do claims require a specific inhaler type in the milling step?
No. The dispersal function is tied to “actuation of an inhaler,” while DPI and pMDI are addressed in dependent product/formulation claims.
3) What is the strongest structural hook for product infringement?
Claims 17-19: additive forms a (discontinuous) coating on active particle surfaces with thickness ≤ 1 μm.
4) What particle size metric is directly claimed?
MMAD: active and additive MMAD reductions of at least 10% during milling (claims 2-3), and composite MMAD ≤ 10 μm after milling (claim 4).
5) Which milling approach is explicitly covered?
Three alternatives in claim 1: passing through a constriction under pressure, compressing in a gap, or jet milling.
References
- User-provided claim text for US Patent 7,736,670 (claims 1-22).
